

AMENDMENTS TO THE CLAIMS

Please add Claims 48-50 as follows:

1-38 PREVIOUSLY CANCELED

1 ~~39~~. (Previously added) An immunogenic composition comprising a lipooligosaccharide (LOS) isolated from *Moraxella catarrhalis* and detoxified by treating to remove esterified fatty acids to produce detoxified LOS (dLOS) and an immunogenic carrier covalently linked thereto.

2 ~~40~~. (Previously added) The immunogenic composition of Claim ~~39~~¹, wherein the immunogenic carrier is a protein.

3 ~~41~~. (Previously added) The immunogenic composition of Claim ~~40~~², wherein the immunogenic carrier protein is selected from the group consisting of UspA isolated from *M. catarrhalis*, CD isolated from *M. catarrhalis*, tetanus toxin/toxoid, a high molecular weight protein (HMP) isolated from nontypeable *Haemophilus influenzae*, diphtheria toxin/toxoid, detoxified *P. aeruginosa* toxin A, cholera toxin/toxoid, pertussis toxin/toxoid, *Clostridium perfringens* exotoxins/toxoid, hepatitis B surface antigen, hepatitis B core antigen, rotavirus VP 7 protein, CRM, CRM₁₉₇, CRM₃₂₀₁ and respiratory syncytial virus F and G protein.

4 ~~42~~. (Previously added) The immunogenic composition of Claim ~~41~~³, wherein the immunogenic carrier protein is tetanus toxoid or HMP.

5 ~~43~~. (Previously added) The immunogenic composition of Claim ~~42~~¹, further comprising an adjuvant.

6 ~~44~~. (Previously added) The immunogenic composition of Claim ~~43~~⁵, wherein the adjuvant is an admixture of monophosphoryl lipid A and trehalose dimycolate or alum.

7 ~~45~~. (Previously added) The immunogenic composition of Claim ~~44~~¹, wherein the immunogenic carrier is covalently linked to dLOS via a linker compound.

8 ~~46~~. (Previously added) The immunogenic composition of Claim ~~45~~⁷, wherein the linker compound is selected from the group consisting of adipic acid dihydrazide, ε-amino hexanoic acid, chlorohexanol dimethyl acetal, D-glucuronolactone and p-nitrophenylethyl amine.

9 ~~47~~. (Previously added) The immunogenic composition of Claim ~~46~~⁷, wherein the linker compound is adipic acid dihydrazide.

Appl. No. : 09/610,034
Filed : July 5, 2000

10/48. (New) The immunogenic composition of Claim 39, wherein said esterified fatty acids have been removed by treatment with hydrazine or a mild alkaline treatment.

11/49. New) The immunogenic composition of Claim 48, wherein said esterified fatty acids have been removed by treatment with hydrazine.

12/50. (New) The immunogenic composition of Claim 39, wherein said dLOS shows a toxicity of 1 EU/ μ g as determined using the limulus amebocyte lysate (LAL) assay.
